Gunderson Dettmer represented Affinivax, a vaccine development company focused on protections against infectious diseases, in its $120 million Series B financing led by Viking Global Investors. Other investors included Bain Capital Life Sciences and Ziff Capital Partners.

In an announcement of the financing Affinivax CEO Steven B. Brugger said, “We are very pleased to welcome such a strong syndicate of new investors to Affinivax and look forward to benefiting from their deep experience. Having built the company to over 70 employees and advanced MAPS into clinical testing in less than 5 years, we are very excited to look ahead to our next phase of growth, taking our lead pneumococcal vaccine through Phase 3 testing and bringing several additional novel MAPS vaccines and immunotherapies into clinical trials.”

The Gunderson deal team was led by partner Timothy Ehrlich and included Chris Crawford, Beatrice Igne-Bianchi, Gabriella Stearns, Erik Thompson and Mary Sullivan.